anim health kol reinforc top-tier reput zoeti kudo
dermatolog portfolio upcom feline/canin pain mab caution express
potenti uptak tripl updat model post rais top-
bottom-lin estim well pt
anim health kol cite zoeti almost unstopp juggernaut insid
veterinari practic reflect breadth innov product offer includ
success dermatolog duo apoquel cytopoint kol still see solid prospect
apoquel/cytopoint benefit first-mov advantag extraordinari
effect entrench product vet owner commun
potenti competitor face uphil battl kol also posit regard
prospect inject feline/canin pain product estim pain market
roughli could doubl cat dog inject option file
felin pain mab approv expect canin version file soon
one area kol less optimist investor potenti
oral tripl parasiticid heartworm file tripl trio
approv expect ye pend label detail expect oral tripl
driven increas conveni kol less convinc signific inroad
made believ certain exist heartworm product strong
brand loyalti conveni aspect give one oral instead two less
import nonetheless addit tripl expand simparica brand
support zoeti innov reput estim simparica sale includ line
extens
growth tie line extens geograph expans upsid trio turn
home run
updat model post result revenu forecast increas
year annual growth remain rang ahead industri
growth revenu estim vs consensu
guidanc ep estim also increas year
line consensu guidanc
year thereaft ep forecast estim assum gpm
remain vicin pend better read
product mix oper margin estim increas annual
given increas ep estim well ad visibl tie
announc file felin pain mab rais pt ep
pleas see page report import disclosur
rate share outperform base rel attract anim health
market solid outlook top- bottom-lin growth versu market
upsid possibl believ execut prospect move share higher
apoquel cytopoint sale trend
sale compound-annual-growth-rate
ep compound-annual-growth-rate
apoquel cytopoint simparica tripl
uptak greater expect
signific product emerg
pipelin feline/canin pain mab
diagnost inroads/sal better
apoquel cytopoint simparica tripl
feline/canin pain mab approv
zoeti inc engag discoveri develop manufactur commerci
anim health medicin vaccin focu livestock companion anim
primari livestock speci cattl beef dairi swine poultri sheep fish
primari companion anim speci dog cat hors zoeti spun
cowen compani
compani data cowen compani
compani data cowen compani
state livestock revenu livestock lc ex companion companion lc ex lc ex revenu contract mfg /human ww lc ex total dog mfg /human revenu cowen
compani data cowen compani
compani data cowen compani
compani data cowen compani
state livestock revenu livestock lc ex companion companion lc ex lc ex revenu contract mfg/human ww lc ex total total dog cowen
compani data cowen compani
compani data cowen compani
compani data cowen compani
state livestock cattl beef dairi swine poultri apoquel cytopoint simparica dx new product drive growthtot ahead market growth revenu driven demand protein especi em livestock lc ex pharmaq farm fish ad companion new product expand pet care dx companion lc ex -restructur lc ex revenu line market growth speci cer new product key apoquel cytopoint simparica contract mfg /human tie former contract abaxi human dx ad aug ww lc ex strong em demand safe protein beef dairi solid demand asf impact on-going steadi demand trend toward antibiotic-fre farm fish ad pharmaq sheep othertot speci trend vari geographicallycompanion total dog new product abaxi line extens drive growth nich markettot could even faster given potenti influx new drugscontract mfg /human activ pursuedtot revenu steadi gain upsid possibl cowen
compani data cowen compani
ceftiofur rev market sinc draxxin rev market sinc anti-infect sku reduct exclud growth promot livestock fish companion anim product parasiticid revolut price/or competit mainli felin use nich dog simparica oral flea tick launch eu topic felin trio review parasiticid mostli livestock fishparasiticid boost pharmaq ionophor grow off-set ractopamin shared-us anti-bio declinesoth product apoquel atop dermat dog expand acute/season use cytopoint canin atop dermat inject total pharma rimadyl sileo surgic med nexvet mab pharma undisclos pipelin product could boost genet test iv fluid embrex devic anim hlth companion anim dx abaxi close product assum small bolt-on acquisitionscontract product suppli agreementstot fx estim cowen
compani data cowen compani
compani data cowen compani
state livestock revenu livestock lc ex companion companion lc ex lc ex revenu contract mfg/human ww lc ex total total dog cowen
compani data cowen compani
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio discount cash flow
competit dynam global potenti regulatori delay reject failur
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk price includ abil re-suppli apoquel success pipelin
product weather/diseas risk busi success independ compani
